trending Market Intelligence /marketintelligence/en/news-insights/trending/nOjVJgeviD1jOpPoNGTu1Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Fortress acquires license for nervous system disorders therapy from AstraZeneca

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Fortress acquires license for nervous system disorders therapy from AstraZeneca

Fortress Biotech Inc. agreed to acquire the exclusive worldwide license of AstraZeneca PLC's experimental nervous system disorders treatment AZD7325.

Under the agreement, Cambridge, U.K.-based AstraZeneca will receive an equity stake in Fortress Biotech's newly formed partner company Baergic Bio Inc.

Additionally, New York-based Fortress Biotech will get clinical data for AZD7325 generated to date. The drug will also be renamed to BAER-101.

Moreover, Fortress Biotech entered into an agreement with Cincinnati Children's Hospital Medical Center to advance clinical development in select central nervous system disorders.